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Abstract
Background—Studies of biomarkers of hypothalamic-pituitary-adrenal (HPA) activity indicate
that psychotic disorders are associated with elevated cortisol. This study examined cortisol levels
in healthy controls and individuals who meet clinical high risk (CHR) criteria for psychosis. It was
hypothesized that cortisol levels would be; a) elevated in the CHR group relative to controls, b)
positively correlated with symptom severity, and c) most elevated in CHR patients who transition
to psychotic level severity.
Methods—Baseline assessments were conducted at eight centers in the North American
Prodrome Longitudinal Study (NAPLS). The present CHR sample included 256 individuals
meeting Structured Interview for Prodromal Syndromes (SIPS) criteria, and 141 controls, all of
whom underwent baseline assessment and measurement of salivary cortisol.
Results—Consistent with previous reports, there was an effect of age on cortisol, with increases
through the adolescent/early adult years. Analysis of covariance (ANCOVA) showed a main effect
of diagnostic group, with the CHR group showing higher cortisol. There were modest, positive
correlations of cortisol with baseline symptom severity, and ANCOVA revealed higher baseline
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cortisol in those who transitioned to psychotic level symptoms when compared to healthy controls
and CHR subjects who remitted.
Conclusions—The present findings add to accumulating evidence of heightened cortisol
secretion in CHR individuals. The findings also indicate nonspecific associations between cortisol
levels and symptom severity, as well as symptom progression. The role of HPA activity in
prediction of conversion to psychosis, and its relation with other biomarkers of risk, should
receive attention in future research.
Keywords
psychosis; prodrome; high-risk; stress; cortisol; longitudinal
Introduction
The role of stress hormones in triggering the expression of vulnerability to mental disorder
has become a significant focus of research.(1) The importance of this area of investigation
has been highlighted by advances in our understanding of neurohormonal signaling,
epigenetic processes, and gene–environment interactions in the etiology of mental disorders.
Within the last decade, a substantial body of literature has accumulated on hypothalamic–
pituitary–adrenal (HPA) function in schizophrenia and other psychoses, and a 2008 review
of the results supports five general conclusions (1): 1) Indices of HPA activity (cortisol and
adrenocorticotropic hormone [ACTH]) are elevated in some patients with schizophrenia and
other psychoses, especially in nonmedicated and first-episode patients; 2) antipsychotic
medications typically reduce cortisol, with more pronounced reductions in drug responders;
3) drugs that augment dopamine (DA) or exacerbate/induce psychotic symptoms also
increase HPA activity; 4) glucocorticoid receptors appear to be down-regulated in psychotic
patients, suggesting reduced negative feedback on the HPA axis, and 5) reduced
hippocampal volume, a correlate of hypercortisolemia, is among the most consistently
reported brain abnormalities in psychotic patients.
Reports published subsequent to the above review have yielded similar findings (2–8). For
example, research has shown elevated cortisol in first episode and recent onset psychotic
patients (3–4), and increased activity of systemic cortisol metabolism in schizophrenia
patients (5). Among mood disorders patients, those with psychotic symptoms manifest
greater elevations in cortisol (6). Further, heightened cortisol levels (7) and more
pronounced cortisol reactivity to daily stress (8) have been observed in relatives of psychotic
patients. Recently, a study of first-episode psychotic patients revealed no differences from
controls in cortisol, but the magnitude of the decrease in cortisol over 12 weeks was
associated with the decline in severity of psychotic, negative, and mood symptoms (9).
Consistent with this, cortisol levels are correlated with severity ratings of a range of
symptoms in psychotic patients (10).
Because many view the prodromal phase as affording the greatest opportunities for
preventive intervention, individuals who manifest clinical signs of psychosis risk (Clinical
High Risk - CHR) have become the focus of research interest. Structured measures for
prospective assessment of the prodrome have been developed (11–12), and individuals who
meet criteria using these measures are shown to have a significantly elevated rate of
conversion to psychosis; 20% to 40% of these individuals subsequently develop a psychotic
disorder (11–13). Further, CHR subjects manifest brain abnormalities similar to those
detected in first-episode patients; namely reduced gray matter volume and white matter
abnormalities (15–18).
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Indices of the biological response to stress are of particular interest during the prodromal
phase, given that stress is assumed to play a role in triggering symptoms. To date, only a few
published reports have explored the HPA system, or its activity, in a CHR or ‘prodromal’
sample (19). In one study, pituitary volume was measured via magnetic resonance imaging
in a CHR group (20). The subjects who later developed psychosis had a significantly larger
baseline pituitary volume compared with those who did not. The authors suggested that the
larger pituitary volume may be indicative of heightened HPA activation (20). However, in
another report on 18 CHR subjects, this same research group found that cortisol showed no
significant relationship with global psychopathology, psychotic symptoms, or pituitary and
hippocampal volumes, but was positively correlated with ratings of depression and anxiety
(21). These investigators also conducted a study in which they administered the
dexamethasone corticotrophin releasing hormone (DEX/CRH) test to twelve CHR subjects
at baseline (22). Three of the twelve developed psychosis within 2 years. Given the small
sample size, statistical analyses were not conducted, but the authors reported that
participants who did not develop psychosis showed a trend toward higher cortisol levels at
the latter stages of the test, when compared to the three participants who did develop
psychosis.
Other studies with larger samples have indicated that CHR subjects do manifest higher
cortisol levels (23–25). A recent report indicates that CHR youth who go on to develop a
psychotic disorder show significantly higher cortisol levels in the year preceding onset (24).
The study included 56 CHR youth, with 14 subsequently converting to a psychotic disorder.
Multiple saliva samples were obtained to enhance cortisol estimation reliability. As in
previous studies of HPA activity in adolescence, an age-related increase in cortisol secretion
was also observed, suggesting that the developmental period of peak risk for prodromal
onset is also characterized by greater stress sensitivity. Other research on CHR samples has
shown an association between cortisol and severity of positive and nonspecific symptoms (2,
19). Finally, a novel study of CHR and psychotic patients measured stress-induced cortisol
and DA release, using PET to index percent change in receptor binding between conditions
(stress versus control) in the limbic, associative, and sensorimotor striatum (25). The stressor
was a challenging mental arithmetic task. Compared to healthy controls, CHR and psychotic
patients had more pronounced DA response in the associative and sensorimotor striatum, as
well as a greater cortisol response to the stressor. Further, there was a significant association
between the increases in cortisol and DA.
With increasing evidence that neurohormones play a role in neuronal function and
epigenetic processes, the importance of research on HPA activity in CHR samples has
become more apparent (26). To date, the research in this area has often utilized nonoptimal
measurement procedures (e g., single assays without controlling for diurnal changes) and
has involved small samples that vary in demographics. The present study extends this line of
investigation in a larger sample of CHR individuals participating in the North American
Prodrome Longitudinal Study (NAPLS). It is hypothesized that the CHR group will show
significantly higher cortisol levels than healthy controls, and that cortisol levels will be




The NAPLS prospective study of prodromal syndromes is an ongoing, collaborative
longitudinal project (27). The objectives are to enhance prediction of psychosis in clinically-
defined high-risk individuals and shed light on the neural mechanisms subserving
conversion. At the half-way mark of baseline data collection, with a sample of 540 (360
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CHR and 180 controls), there is adequate power to conduct data analyses aimed at
addressing key hypotheses. The second half of the baseline sample will provide the
opportunity for replication analyses.
The present investigation includes those participants, of the 540 assessed at baseline, for
whom dietary information and saliva for assay were obtained, and the samples were
adequate for assay. These data were available for 397 participants; 256 CHR subjects (146
males, 110 females) who met prodromal syndrome criteria and 141 (76 males, 65 females)
healthy controls. This subsample comprises all participants in the NAPLS project, as of the
study midpoint, for whom at least one saliva sample for baseline cortisol assay was available
(27). The age range of all participants was 12 to 35 years with a mean age of 19 (SD=4.2)
for the CHR group and 19.1 (SD= 4.6) for the control group.
The protocol was approved by Institutional Review Boards at all NAPLS sites where data
were collected (Emory University, Harvard University, University of Calgary, University of
California Los Angeles (UCLA), University of California San Diego (UCSD), University of
North Carolina (UNC), Yale University, and Zucker Hillside Hospital), and all participants
provided informed consent or assent (and parental informed consent) for minors.
ASSESSMENT PROCEDURES AND MEASURES
Participants were screened using the Structured Interview for Prodromal Syndromes (SIPS)
(11) at initial assessment and follow-ups. The SIPS contains the Scale of Prodromal
Symptoms (SOPS) which rates the severity of symptoms with the following scale: 0 =
absent, 1 = questionably present, 2 = mild, 3 = moderate, 4 = moderately severe, 5 = severe
but not psychotic, and 6 = very severe and psychotic. The rated symptoms comprise four
domains; positive (e.g., unusual thoughts or ideas, suspiciousness, perceptual abnormalities,
disorganized communication), negative (e.g., social isolation, avolition, decreased
expression of emotion, decreased ideational richness, deteriorated role function),
disorganized (e.g., odd behavior, bizarre thinking, trouble with focus and attention), and
general (sleep disturbance, dysphoric mood, impaired stress tolerance, and motor
disturbances). Following SIPS procedures, subjects were designated as prodromal if they
met one or more of four sets of criteria; 1) Brief Intermittent Psychotic Syndrome (BIPS) if
rated a 6 on one positive symptom in the past 3 months, Attenuated Positive Symptom
(APS) syndrome if rated a 3, 4, or 5 on at least one positive symptom, 3) Genetic Risk and
Deterioration Syndrome (GRDS) in a person with a first degree relative with a nonaffective
psychotic disorder who shows a steep functional decline over the past year, or 4) meeting
criteria for Schizotypal Personality disorder (SPD) at the age of 18 or under. Individuals in
the CHR group can meet criteria for more than one prodromal syndrome. Among the sample
of 256 CHR participants in the present study, 89% met criteria for APS, 18% met criteria for
GRD, 14% met criteria for SPD, and 3% met criteria for BIPS.
The Structured Clinical Interview for Axis I DSM–IV Disorders (28) was administered to
diagnose Axis I disorders at the initial and annual follow-up assessments. The SCID–I/P was
utilized to maintain consistency in the diagnostic procedure across participants and over
time as they entered young adulthood through the longitudinal course of the study.
A detailed description of the study procedures is presented in detail elsewhere (27). In brief,
CHR participants were excluded if they had ever met DSM-IV criteria for an Axis I
psychotic disorder. Control participants were excluded if they met criteria for an Axis I
psychotic disorder, had a first-degree relative with a current or past psychotic disorder, or
met prodromal criteria. General exclusions included substance dependence, neurological
disorder, or Full Scale IQ <70.
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Assessments were conducted by trained interviewers who met reliability standards for the
project (27). Interviewers were clinical psychologists, psychiatrists, and other mental health
staff. Cross-site reliability in symptom ratings was established prior to study initiation and
on a yearly basis. The kappa statistic was used to compare trainee agreement with the “gold
standard” diagnosis on the SOPS ratings. Within all sites, intra-class correlations for the
symptom ratings exceeded .80, thus were high.
SALIVA COLLECTION AND ASSAY
Participants were provided with dietary instructions to observe the evening before and the
morning of sampling. These included refraining from caffeine, alcohol, dairy products, and
nonprescription medications. They were queried to confirm compliance with these
instructions.
Saliva samples for cortisol assay were obtained three times during baseline assessment in the
research clinic, prompted by a timer to be approximately on the hour (i e, over two hours),
beginning on average about 10:00 a.m., with a range from 9:00 to 11:30 a.m. at onset of
sampling (SD= 26 minutes), and no difference between the groups in time of sampling
onset, t(1,396) = 1.39, p=.17). Multiple saliva samples (n = 3) were obtained to derive an
average and increase the reliability of the cortisol estimate (29).
Saliva was stored in a −20°C freezer. In preparation for assay, samples are rapidly thawed
and centrifuged. All samples are assayed for salivary cortisol (ug/dl) using a highly sensitive
enzyme immunoassay (Salimetrics, State College, PA). The test uses about 25 micro liter of
saliva (for singlet determinations), has a range of sensitivity from 0.007 to 1.8 mg/dl, and
average intra- and interassay coefficients of variation of less than 10% and 15%. All samples
are assayed in duplicate.
DATA ANALYSES
Statistical analyses were conducted with PASW statistics 18 (SPSS Inc, Chicago, Illinois)
statistical software. Independent sample t-tests or chi-square tests were used to compare the
CHR and control groups on demographic and clinical characteristics, and analyses of
covariance (ANCOVA) was used to test group differences in cortisol. Correlational analyses
were conducted to examine the relation of cortisol levels with symptom ratings.
For purposes of normalizing the distribution of age for analysis, the sample was divided into
eight age groups; 12–13 year, 14–15 years, 16–17 years, 18–19 years, 20–21 years, 22–23
years, 24–25 years, and 26–35 years. The later part of the sampled age range was collapsed
due to smaller numbers of subjects at each year over the age of 26 years.
Saliva was available for all 397 subjects at first sampling, but fewer had data for the second
(1% missing) and third (11% missing) samples obtained on the same day. The current
consensus in addressing missing data favors multiple imputation (MI), which avoids
problems inherent in mean substitution and exclusion of cases with missing data (30).
Further, MI retains the error variance lost from regression-based single imputation
approaches. For the present data set, missing value analysis was first conducted using
PASW to examine the pattern of missing values for cortisol at the second and third samples,
then MI was conducted with PASW, using fully conditional specification (31). The results
of the analyses with imputed data are presented below. (When the analyses were conducted
without imputation, the same pattern of results was obtained.)
Walker et al. Page 6















Consistent with the demographics presented in the recently published overview of the
project (27), the CHR and control groups did not differ on age (t (1,396) = .19, p=.86), sex
(X2 (1) = .007, p=.973) or ethnicity (X2 (9) = 7.1, p=.63). The demographic characteristics
of the sample are shown in Table 1.
ANALYSES OF CORTISOL DATA
Analyses showed significant correlations among the 3 salivary cortisol samples; samples 1
& 2, r =.74, p<.001, samples 2 & 3, r = .76, p<.001, and samples 1 & 3, r = .62, p<.001,
indicating reliability of the assay. Mean cortisol across the 3 samples was derived for each
subject.
Preliminary analyses were conducted to identify correlates of cortisol for inclusion as
covariates in analyses of diagnostic group differences. Because some prodromal subjects
were on psychotropic and other medications when they entered the study, analyses were also
conducted to examine the relation of medication with cortisol. These analyses revealed no
significant relation of mean cortisol with antipsychotics (p=.53), antidepressants (p=.99),
stimulants (p=.50), or mood stabilizers (p=.12) in the prodromal group, and no relation with
birth control medication in the females (p=.43).
As expected, correlational analyses revealed a significant inverse relation between time of
onset of saliva sampling and mean cortisol, r = −.12, p<.01. This reflects the normal diurnal
decline in morning cortisol. Thus sampling time was included as a covariate in subsequent
analyses. T-tests revealed no significant relation between cortisol and alcohol, dairy, or
caffeine consumption, subsequent to 7 pm the night before saliva sampling. But those who
reported tobacco use had higher cortisol values than nonusers (t(1, 396)=2.50, p<.05).
Tobacco use was also included as a covariate in analyses.
ANCOVAs, with sampling time and tobacco use as covariates, revealed no significant
differences in mean cortisol as a function of sex or ethnicity, but consistent with previous
reports, there was a significant difference as a function of age group, with higher levels
associated with increasing age, F(7,387)=2.70, p<.01.
Cortisol data were analyzed in a one-way (diagnostic group: CHR versus Control)
ANCOVA, with age group, time at onset of saliva sampling and tobacco use as covariates.
The results yielded a significant main effect for diagnostic group, F(1,392)=5.05, p<.05,
with higher levels in the CHR group. (See Figure 1.)
THE RELATION OF CORTISOL WITH BASELINE SYMPTOM SEVERITY
Correlational analyses were conducted to examine the relation of cortisol with ratings of
symptoms severity for the four prodromal symptom scales. Significant, modest, positive
correlations with cortisol were obtained for the positive, r =.13, p<.01, negative, r =.09, p<.
05, general, r =.11, p<.05, and disorganized symptom ratings, r =.11, p<.05. As described,
among the general symptoms there are four items, including separate ratings of dysphoric
mood and impaired stress tolerance. Because of the potential relevance of these individual
items to cortisol levels, they were examined separately. The correlations between baseline
cortisol and symptom ratings were significant for dysphoric mood r =.11, p<.05, and
impaired stress tolerance, r =.12, p<.05, but not sleep disturbance, r =.08, p=.09, or motor
disturbances, r =.00, p=49.
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At the time of this writing, follow-up assessments of CHR participants are ongoing, so the
final conversion rate is not yet known. And, of those who have reached a psychotic level of
severity on the SIPS, the DSM diagnosis has not yet been established for all. In the interim,
in order to determine whether baseline cortisol is linked with symptom progression,
preliminary analyses were conducted using data for those 136 CHR subjects in the present
sample who had been followed at least 24 months without manifesting psychotic symptoms
or had reached a psychotic level of symptom severity based on the SIPS. The exclusion of
CHR subjects who were not yet followed 24 months and had not transitioned reduced the
likelihood of including false negatives. The following categorization was used: remission
(n=43) (all positive symptoms are rated less than 3), symptomatic (n=37) (one or more of
positive symptoms in the previous 4 weeks were rated 3 – 5, but with no increase in last
year), prodromal progression (n=24) (continues to meet prodromal criteria with one or more
positive symptom rated 3–5 and increasing in severity), or psychotic (n=32) (has increased
to a rating of 6 on one or more positive symptoms).
Cortisol data were analyzed in a one-way (diagnostic group; controls, remission,
symptomatic, prodromal progression, or psychotic) ANCOVA, with age, time at onset of
saliva sampling, and tobacco use as covariates. There was a significant main effect for
diagnostic group, F(4,346)=2.46, p<.05, with posthoc groups contrasts showing that CHR
subjects in the psychotic group had significantly higher baseline cortisol than those in the
control (p=.01) and remission (p=.03) groups. There were no other significant group
differences. (See Figure 2.)
DISCUSSION
This study examined cortisol levels in healthy controls and subjects designated as CHR for
psychosis. As previously reported, there was an age-related increase in cortisol through
adolescence/young adulthood, for both diagnostic groups. Also, as predicted, the CHR group
showed significantly higher cortisol levels than controls, and cortisol levels were correlated
with ratings of symptom severity at baseline and with the progression of prodromal
syndromes.
The finding of nonspecific and modest relations between symptom severity and cortisol
levels is consistent with several previous reports (8–10). The small magnitude of the
correlations may partially reflect the restricted range of symptom severity ratings (0 to 5)
utilized by the SIPS and similar measures for the prodromal range, with a rating of 6 being
at the psychotic level of severity and rarely occurring at baseline. Also relevant to consider
is that the correlations are based on cross-sectional data and may be diminished by
individual differences in sensitivity to the effects of glucocorticoids on brain and behavior.
Thus the relations might be more pronounced in within-subjects designs where the
covariance between cortisol and symptoms is measured longitudinally.
Though preliminary, the analyses of the interim outcome data suggest that baseline cortisol
is linked with the progression of the prodrome; those who transition to the level of 6 or
higher on one or more of the SIPs positive symptoms showing the highest cortisol level. Of
course, the CHR group has only been followed to a maximum of two years, and it has been
shown that there are a substantial number of transitions to psychosis that occur beyond the
second year after prodrome ascertainment. It should therefore be assumed that there are false
negatives in this interim outcome measure. When the entire NAPLS CHR sample is
recruited and the follow-up diagnostic assessments completed, we will conduct analyses that
include specific DSM diagnostic outcomes,
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The current and similar previous findings raise questions about the relation between
heightened HPA activity and risk for psychosis. Is heightened cortisol the consequence of
developing clinical risk symptoms or does it play a role in triggering or exacerbating
symptoms? The symptoms of the CHR syndromes are often subjectively stressful, and it is
plausible that this distress activates the HPA axis. Alternatively, as implied in diathesis–
stress models, the causal relation may be in the opposite direction, such that biological stress
systems trigger the expression of symptoms in some CHR individuals.
There are a variety of potential neural mechanisms through which heightened cortisol
secretion might trigger or exacerbate psychotic symptoms, as well as the cognitive deficits
that often accompany them (32). Animal and human research has shown that HPA activation
can augment dopamine activity (33–38). In nonhuman primates, stress-induced cortisol
levels are associated with higher binding of a dopamine agonist to striatal D2/D3 receptors
as measured by PET (36). Similar results have been reported with CHR and normal human
subjects, such that cortisol levels are correlated with amphetamine-induced DA release in
the striatum (37–38). These findings suggest that HPA activity may be linked with psychosis
via transient effects on DA. Consistent with this interpretation, daily, repeated measurement
of cortisol and symptoms showed that first-degree relatives of psychotic patients manifested
increases in psychotic experiences in conjunction with increased cortisol (8).
It is also possible that genomic mechanisms are mediating effects of HPA activity on
vulnerability to psychotic symptoms via intracellular receptors (39–46). Genomic
mechanisms, via nuclear receptors, can regulate gene expression and modulate brain
development. There is extensive evidence from experimental animal research that steroid
hormones affect brain organization during adolescence (41), and recent data indicate similar
effects in humans (42, 43). Several recent studies of human subjects also show an inverse
relation of baseline cortisol with cortical gray matter and hippocampal volume (44, 45). As
noted above, the prodrome is associated with brain changes, including reduced gray matter
volume, beyond that observed in healthy controls (15–18). Cortisol levels outside the
normative range may be altering gene expression and contributing to these more pronounced
volumetric declines via modulation of BDNF and other aspects of neurogenesis (47–50).
Alternatively, some CHR subjects may have vulnerability genes that are being triggered by
heightened cortisol. Finally, genes involved in cortisol metabolism may be among the risk
genes for psychotic disorders (5).
In addition to the issue of the relation between cortisol and brain abnormalities, the complex
interplay between cortisol levels and receptor characteristics is relevant. There is a dynamic
relation of cortisol activity with glucocorticoid (GC) and mineralocorticoid (MR) receptors
and with the genes that govern their expression (51–53). The effect of cortisol on brain and
behavior would be expected to vary as a function of receptor characteristics. Thus,
measurement of receptors, when combined with measures of cortisol, may yield a more
complete picture of the role of the HPA axis in psychosis. To date, the few studies of
receptors in psychotic disorders indicate reductions in brain GR mRNA (54–55), and MR
mRNA expression (56).
The primary limitation of the present, and most other studies of CHR subjects, is the absence
of control over psychotropic medications. A subgroup of the present sample was on a
psychotropic medication, and the protocol did not require medication withdrawal. Although
we found no relation between psychotropics and cortisol, as described above, previous
longitudinal studies have revealed that atypical antipsychotics reduce cortisol levels (1, 57).
If pre-baseline symptom severity was a precipitant of antipsychotic prescription in the
present sample, as would be expected, the result may have been a reduction in baseline
cortisol levels and symptoms for the medicated subgroup. In other words, medicated
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participants may have had higher pre-baseline cortisol levels and symptoms that were
lowered with medication, thereby attenuating the difference between the medicated and
nonmedicated CHR participants. This possibility can be examined in subsequent studies of
this sample, as medication changes are monitored longitudinally in conjunction with
cortisol.
As noted above, this is an ongoing study and follow-ups are not complete, thus we do not
know the eventual rate of psychosis or the optimal set of predictors of conversion.
Nonetheless, the present sample exceeds that of most CHR studies, and the second half of
the sample will provide opportunities for replication. These studies will address questions
concerning the relation of cortisol with other biomarkers, symptom progression, and
diagnostic outcome, as well as heterogeneity among CHR converters in these relations. With
respect the latter, it is of interest to determine whether hypersecretion of cortisol
characterizes an etiological subgroup.
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Table 1
Demographic and Clinical Characteristics
Healthy Controls Clinical High Risk (CHR)
Number of Participants (N=397) 141 256
Age, years (SD) 19.1 (4.6) 19 (4.2)
Sex, male/female 76/65 146/110
Education, years (SD) 12.17 (3.52) 11.72(2.64)
Current Psychotropic medication, % 0% 25%
Race/ethnicity (%)
First Nations 2% 2%
East Asian 4% 2%
Southeast Asian 2% 2%
South Asian 2% 3%
Black 15% 14%
Central/South American 4% 6%
West/Central Asia and Middle East 1% 1%
White 58% 54%
Native Hawaiian or Pacific Islander 1% 1%
Interracial 11% 15%
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